Salix has an exclusive license to the patent protecting Osmoprep from CDC III, for commercialization of Osmoprep in the US.
The lawsuit is in response to an abbreviated new drug application filed by Novel with the FDA regarding Novel’s intent to market a generic version of Osmoprep in the US prior to the May 18, 2013 expiration of US patent.
Salix said that it has full confidence in the intellectual property rights that protect Osmoprep. Moreover, Salix intends to use all reasonable means at its disposal to continue to vigorously defend and enforce the intellectual property rights protecting Osmoprep.